ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1089

Trajectories of Disability over Time Among Patients with Systemic Sclerosis

Sarah D. Mills1, Rina S. Fox1, Shadi Gholizadeh2, Scott C. Roesch1,3, Murray Baron4,5, Marie Hudson6,7, Russell Steele6,8, Brett D. Thombs6,9 and Vanessa L. Malcarne1,10, 1SDSU/UCSD Joint Doctoral Program in Clinical Psychology, San Diego, CA, 2Psychology, SDSU/UCSD Joint Doctoral Program in Clinical Psychology, San Diego, CA, 3Psychology, San Diego State University, San Diego, CA, 4Pavillion A, Rm 216, Jewish General Hospital, Montreal, QC, Canada, 5McGill University, Montreal, QC, Canada, 6Jewish General Hospital, Montreal, QC, Canada, 7Division of Rheumatology, McGill University, Montreal, QC, Canada, 8Mathematics, McGill University, Montreal, QC, Canada, 9Psychiatry, McGill University, Montreal, QC, Canada, 10San Diego State University, San Diego, CA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Disability, longitudinal studies and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Public Health (ARHP): Epidemiology and Public Health

Session Type: Abstract Submissions (ARHP)

Background/Purpose

Systemic Sclerosis (SSc) is often associated with disability, which worsens over time. However, there is considerable heterogeneity in the rate of patients’ disability progression. The aim of the present study was to identify homogenous subpopulations of SSc patients with distinct trajectories of change in disability over a three-year period.

Methods

The sample included patients with limited and diffuse SSc (N = 1,125) participating in the Canadian Scleroderma Research Group Registry. As part of the Registry, patients are scheduled for annual follow-up visits. Patients with and without follow-up visits were included to account for potentially informative patient drop out. Growth mixture modeling (GMM) with robust maximum likelihood estimation was completed to identify groups of patients with distinct trajectories of disability over a three-year period, as measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI; range: 0 (no disability) – 3 (severe disability)). Multinomial logistic regression was used to identify baseline sociodemographic and clinical variables that predicted membership in the latent growth trajectory classes. 

Results

Considering fit indices (AIC, sBIC, BLRT) and substantive interpretation (class proportions, entropy), the GMM analysis identified three distinct groups of patients based on their disability trajectories. Class 1 was comprised of 53.4% of the total sample, and Classes 2 and 3 were comprised of 35.3%, and 11.2% of the total sample, respectively. Based on trajectories of HAQ-DI scores the groups were named: Minimal Disability-Increasing (Class 1; baseline HAQ-DI: .27), Moderate Disability-Stable (Class 2; baseline HAQ-DI: 1.20), and Severe Disability-Stable (Class 3; baseline HAQ-DI: 2.04). In Class 1, HAQ-DI scores increased by .12 over three years. Patients in Class 3 had more finger ulcers, more breathing problems, and more gastrointestinal problems than patients in Class 2 or Class 1. In addition, patients in Class 3 were of older age, had shorter disease duration, and were more likely to be female and have diffuse disease than patients in Class 1.  Patients in Class 2, when compared to Class 1, had more finger ulcers, breathing problems, and severe Raynaud’s phenomenon, and were more likely to be older, female, and have diffuse disease.

Conclusion

Disability trajectories are not uniform across patients with SSc. Overall, patients with low baseline disability scores and disability progression had fewer finger ulcers, breathing problems, and gastrointestinal problems, less severe Raynaud’s phenomenon, were of younger age, male, had longer disease duration, and limited disease in comparison to the moderate and severe disability groups. The moderate and severe disability groups did not report significant disability progression, suggesting that for at least some patients with SSc, disability may reach a peak and then remain stable overtime.


Disclosure:

S. D. Mills,

Rheumatology Research Foundation,

2;

R. S. Fox,
None;

S. Gholizadeh,
None;

S. C. Roesch,
None;

M. Baron,

American College of Rheumatology Research and Education Foundation ,

2,

Fonds de la Recherche en Santé du Québec ,

2,

Canadian Institutes of Health Research,

2,

Scleroderma Society of Canada ,

2,

INOVA Diagnostics Inc. ,

2,

Dr. Fooke Laboratorien GmbH,

2,

Euroimmun,

2,

Mikrogen GmbH ,

2,

Fonds de la recherche en du Québec – Santé,

2,

Lady Davis Institute of Medical Research of the Jewish General Hospital,

2,

Pfizer Inc,

2,

Actelion Pharmaceuticals US,

2;

M. Hudson,

American College of Rheumatology Research and Education Foundation,

2,

Fonds de la Recherche en Santé du Québec ,

2,

Canadian Institutes of Health Research,

2,

Scleroderma Society of Canada ,

2,

INOVA Diagnostics Inc,

2,

Dr. Fooke Laboratorien GmbH ,

2,

Euroimmun,

2,

Mikrogen GmbH ,

2,

Fonds de la recherche en du Québec – Santé ,

2,

Canadian Arthritis Network,

2,

Lady Davis Institute of Medical Research of the Jewish General Hospital,

2,

Pfizer Inc,

2,

Actelion Pharmaceuticals US,

2;

R. Steele,

American College of Rheumatology Research and Education Foundation,

2,

Fonds de la Recherche en Santé du Québec ,

2,

Canadian Institutes of Health Research,

2,

Scleroderma Society of Canada ,

2,

INOVA Diagnostics Inc,

2,

Dr. Fooke Laboratorien GmbH,

2,

Euroimmun,

2,

Mikrogen GmbH ,

2,

Fonds de la recherche en du Québec – Santé ,

2,

Canadian Arthritis Network,

2,

Lady Davis Institute of Medical Research of the Jewish General Hospital,

2,

Pfizer Inc,

2,

Actelion Pharmaceuticals US,

2;

B. D. Thombs,

American College of Rheumatology Research and Education Foundation,

2,

Arthritis Society,

3,

Fonds de la Recherche en Santé du Québec ,

2,

Canadian Institutes of Health Research,

2,

Scleroderma Society of Canada ,

2,

INOVA Diagnostics Inc,

2,

Dr. Fooke Laboratorien GmbH,

2,

Euroimmun,

2,

Mikrogen GmbH ,

2,

Fonds de la recherche en du Québec – Santé ,

2,

Canadian Arthritis Network,

2,

Lady Davis Institute of Medical Research of the Jewish General Hospital,

2,

Pfizer Inc,

2,

Actelion Pharmaceuticals US,

2;

V. L. Malcarne,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/trajectories-of-disability-over-time-among-patients-with-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology